Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lyle Murphy

Physician Assistant, Medical Galesburg, IL Physician Assistant

NPI 1235324450 CMS profile 10757688

3315 N Seminary St, Galesburg, IL 61401

Open in the dashboard

General payments

$6,756

217 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lyle Murphy of Galesburg, IL is reported in the CMS Open Payments database as having received $6,756 across 217 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,015 80
2024 General $2,043 46
2023 General $916 11
2022 General $747 35
2021 General $1,035 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lyle Murphy
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Lyle Murphy were reported at $2,015. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Lyle Murphy Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,035 $156 $41–$563 $132
2022 $747 $185 $55–$649 $149
2023 $916 $199 $58–$717 $160
2024 $2,043 $206 $62–$740 $164
2025 $2,015 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $1,022 31 payments
  2. AstraZeneca Pharmaceuticals LP $952 23 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $686 30 payments
  4. Amgen Inc. $611 19 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $383 22 payments
  6. GlaxoSmithKline, LLC. $353 3 payments
  7. Sanofi-Aventis U.S. LLC $348 13 payments
  8. Novartis Pharmaceuticals Corporation $342 18 payments
  9. AbbVie, Inc. $294 10 payments
  10. Genzyme Corporation $254 2 payments
  11. Other $1,512 46 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,756 217 payments
Products named General payments · program years 2021–2025
  1. Wegovy $561 16 payments
  2. EVENITY $481 17 payments
  3. Ozempic $461 15 payments
  4. FARXIGA $453 11 payments
  5. JARDIANCE $399 21 payments
  6. Kerendia $383 22 payments
  7. DUPIXENT $375 3 payments
  8. NURTEC ODT $360 12 payments
  9. AREXVY $353 3 payments
  10. LEQVIO $342 18 payments
  11. Other $3,653 134 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 154 drugs

Part D claims

10,659

Median for Physician Assistant: 241

Drug cost

$934,178

Median for Physician Assistant: $4,110

Branded share of claims

23.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 259 $206,142
Eliquis Apixaban Brand 159 $173,848
Ozempic Semaglutide Brand 104 $110,170
Xarelto Rivaroxaban Brand 55 $58,610
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 48 $32,286
Tradjenta Linagliptin Brand 41 $29,754
Rybelsus Semaglutide Brand 19 $29,312
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 38 $27,996
Entresto Sacubitril/Valsartan Brand 19 $20,371
Farxiga Dapagliflozin Propanediol Brand 22 $19,916

The 10 drugs with the highest cost, of 154 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $265
$265 22 —
AREXVY
  • GlaxoSmithKline, LLC. $233
$233 — —
Wegovy
  • Novo Nordisk Inc $212
$212 — —
EVENITY
  • Amgen Inc. $170
$170 — —
QULIPTA
  • AbbVie, Inc. $164
$164 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

217 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record